Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer-Reference-Cited by-同舟云学术

Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer

Published:2021-06 Issue: Volume:162 Page:103351
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Berti Alvise,Bortolotti Roberto,Dipasquale Mariachiara,Kinspergher Stefania,Prokop Larry,Grandi Guido,Inchiostro Sandro^ORCID,Paolazzi Giuseppe,Caffo Orazio,Veccia Antonello^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference37 articles.

1. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group;Puzanov;J Immunother Cancer.,2017

2. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol.,2017

3. Management of Immunotherapy-Related Toxicities, Version 1.2019;Thompson;J Natl Compr Canc Netw.,2019

4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N Engl J Med.,2015

5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;Borghaei;N Engl J Med.,2015

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

5. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04